Summary
The basic pharmacology of dihydropyridine Ca-agonists published so far (BAY k8644, CGP 28–392, H 160/51, YC 170, and 202–791) is described. The importance of the potency of the enantiomeres for the effect of a racemic compound is underlined.
The Ca agonist prototype BAY k8644 leads to an increase of the maximal rate of rise of left ventricular pressure (LV(dP/dt)) and an increase of left ventricular stroke work in conscious dogs. When the vascular effects of BAY k8644 are counterbalanced by intravenous injection of sodiumnitroprusside, the left ventricular functions curves show markedly increased stroke work against the same mean arterial blood pressure at the same filling pressure.
BAY k8644 stimulates the heart economically: the net efficiency in isolated working guinea-pig hearts is about 20%, identical to a stimulation by calcium or ouabain. Cardiotonic drugs acting via cAMP-dependent mechanisms like isoprenaline, amrinone, or pimobendane however, stimulate the heart about 1/3 less economically.
The mechanism of action of Ca-agonists is explained from electrophysiological findings: Ca-agonistic dihydropyridines increase the open probability of the Ca-channels by a shift of the open-probability curve to more negative membrane potentials. As a consequence, the steady-state inactivation curve of the Ca-channel is also shifted in the same direction. While the effect on open-probability is the underlying mechanism for Ca-agonism, the latter effect results in Ca-antagonism. Therefore, depending on drug concentration and on membrane resting potential, a single chemical compound can act either as a Ca-agonist or a Ca-antagonist. A kinetic model of dihydropyridine action on the Ca-channel is described.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Bechem M, Pott L (1985) Removal of Ca-current inactivation in dialyzed guinea-pig atrial cardioballs by Ca-chelators. Pflügers Arch 404: 10–20
Bechem M, Schramm M (1987) Calcium Agonists. J Mol Cell Cardiol 19 (Suppl II): 63–75
Bechem M, Schramm M (1988) The effects of Ca-agonists and Ca-antagonists on the Ca-current. In: Piper HM, Isenberg G (eds) isolated adult cardiomyocytes. CRC Press (in press)
Bellemann P, Ferry D, Lübbecke F, Glossmann H (1981) 3H-Nitrendipine, a potent calcium channel antagonist binds with high affinity to cardiac membranes. Arzneim Forsch/Drug Res 31: 2064–2067
Beyer T, Gansohr N, Gjörstrup P, Ravens U (1986) The effects of the cardiotonic dihydropyridine derivatives BAY k8644 and H160/51 on post-rest adaptation of guinea-pig papillary muscles. Naunyn-Schmiedeberg’s Arch Pharmacol 334: 488–495
Beyer T, Gjörstrup P, Ravens U (1985) Comparison of the cardiac effects of the dihydropyridine-derivative H160/51 with those of the “Ca-agonist” BAY k8644. Naunyn-Schmiedeberg’s Arch Pharmacol Suppl 330: R34
Campbell AK (1983) Intracellular calcium: its universal role as regulator. Wiley, New York
Curtis BM, Catterall WA (1984) Purification of the calcium antagonist receptor of the voltage-sensitive calcium channel from skeletal muscle transverse tubules. Biochemistry 23: 2113–2118
Erne P, Burgisser E, Bühler FR, Dubach B, Kühnis H, Meier M, Rogg N (1984) Enhancement of calcium influx in human platelets by CGP 28392, a novel dihydropyridine. Biochem Biophys Res Comm 118: 842–847
Franckowiak G, Bechem M, Schramm M, Thomas G (1985) The optical isomers of the 1,4-dihydropyridine BAY k8644 show opposite effects on Ca-channels. Europ J Pharmacol 114: 223226
Gjörstrup P (1985) Effects of H160/51, a new Ca-agonist, and its interaction with felodipine on cardiac and vascular tissue in vitro. Proc Cardiovascular Pharmacotherapy. Intern Symposium Geneva April 22–25, Abstr. 127
Gjörstrup P, Harding H, Isaksson R, Westerlund C (1986) The enantiomers of the dihydropyridine derivative H160/51 show opposite effects of stimulation and inhibition. Eur J Pharmacol 122: 357–361
Glossmann H, Ferry DR, Goll A, Striessnig J, Schober M (1985) Calcium channels: basic properties as revealed by radioligand binding studies. J Cardiovasc Pharmacol 7 Suppl 6: S20 — S30
Gross R, Kayser M, Schramm M, Taniel R, Thomas G (1985) Cardiovascular effects of the Calcium-agonistic dihydropyridine BAY k8644 in conscious dogs. Arch Internat Pharmacodyn Ther 277: 203–216
Haas H, Härtfelder G (1962) c-Isopropyl-c-(N-methyl-homoveratryl)-y-aminopropyl-3,4-dimethoxy-phenylacetonitril, eine Substanz mit coronargefäßerweiternden Eigenschaften. Arzneim Forsch 12: 549–558
Hess P, Lansmann JB, Tsien RW (1984) Different modes of calcium channel gating behaviour favoured by dihydropyridine Ca agonists and antagonists. Nature 311: 538–544
Hof RP, Rüegg UT, Hof A, Vogel A (1985) Stereoselectivity at the calcium channel: opposite action of the enantiomeres of a 1,4-dihydropyridine. J Cardiovasc Pharmacol 7: 689–693
Kokobun S, Reuter H (1984) Diyhdropyridines derivatives prolong the open state of Ca channels in cultured cells. Proc Natl Acad Sci USA 81: 482–527
Marty A, Neher E (1983) Tight-seal whole-cell recording. In: Sakmann B, Neher E (eds) Single channel recording. Plenum, New York, pp 107–122
Nakaya H, Hattori Y, Tohse N, Kanno M (1986) Voltage-dependent effects of YC-170, a dihydropyridine calcium channel modulator in cardiovascular tissue. Naunyn-Schmiedeberg’s Arch Pharmacol 333: 421–430
Preuss KC, Brooks HL, Gross GJ, Warltier DC (1985) Positive inotropic actions of the calcium channel stimulator, BAY k8644, in the awake, unsedated dog. Bas Res Cardiol 80: 326–332
Preuss KC, Chung NL, Brooks HL, Warltier DC (1984) Cardiovascular effects of the nifedipine analog CGP 28392 in the conscious dog. J Cardiovasc Pharmacol 6: 949–953
Rasmussen H, Barret PQ (1984) Calcium messenger system: an integrated view. Physiol Rev 64: 938–984
Sanguinetti MC, Kass RS (1984) Regulation of cardiac calcium channel current and contractile activity by the dihydropyridine BAY k8644 is voltage dependent. J Mol Cell Cardiol 16: 667670
Sarnoff SJ, Mitchell JH (1961) The control of the function of the heart. In: Handbook of physiology, circulation sect 2, vol 1. Am Physiol Soc, Washington
Schramm M, Thomas G, Towart R, Franckowiak G (1983) Novel dihydropyridines with positive inotropication through activation of Ca’ channels. Nature 303: 535–537
Schramm M, Thomas G, Towart R, Franckowiak G (1983) Activation of calcium channels by novel 1,4-dihydropyridines. Arzneim-Forsch 33: 1268–1272
Schramm M, Towart R (1985) Modulation of calcium channel function by drugs. Life Sci 37: 1843–1860
Schramm M, Towart R (1988) Calcium channels as drug receptors. In: Baker PF (ed) Handbook of experimental pharmacology, vol 83. Springer, Berlin Heidelberg New York, pp 89–114
Siess M, Stieler K, Seifart HJ (1981) Zur Wirkung von ARL-115 BS auf Funktion and Sauerstoffverbrauch isolierter Meerschweinchenherzvorhöfe im Vergleich zu g-Strophantin and Theophyllin. Arzneim Forsch/Drug Res 31: 165–170
Takenaka T, Maeno H (1982) A new vasoconstrictor 1,4-dihydropyridine derivative, YC-170. Jap J Pharmacol 132: 139 P
Tanabe T, Takeshima H, Mikami A, Flockerzi V, Takahashi H, Kangawa K, Kojima M, Matsuo H, Hirose T, Numa S (1987) Primary structure of the receptor for calcium channel blockers from skeletal muscle. Nature 328: 313–318
Thomas G, Groß R, Schramm M (1984) Calcium channel modulation: ability to inhibit or promote calcium influx resides in the same dihydropyridine molecule. J Cardiovasc Pharmacol 6: 1170–1176
Thomas G, Chung M, Cohen CJ (1985) A dihydropyridine (BAY k8644) that enhances calcium currents in guinea pig and calf myocardial cells. Circ Res 56: 87–96
Thomas G, Groß R, Pfitzer G, Rüegg JC (1985) The positive inotropic dihydropyridine BAY k8644 does not affect calcium sensitivity or calcium release of skinned cardiac fibres. NaunynSchmiedeberg’s Arch Pharmacol 328: 378–381
Triggle DJ, Janis RA (1987) Calcium channel ligands. Rev Pharmacol Toxicol 27: 347–369
Vater W, Kroneberg G, Hoffmeister F, Kaller H, Meng K, Oberdorf A, Puls W, Schloßmann K, Stoepel K (1972) Zur Pharmakologie von 4-(2’Nitrophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarbonsäuredimethylester (Nifedipin, BAY a1040). Arzneim Forsch 22: 1–14
Author information
Authors and Affiliations
Editor information
Rights and permissions
Copyright information
© 1989 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Bechem, M., Gross, R., Hebisch, S., Schramm, M. (1989). Ca-Agonists: a new class of inotropic drugs. In: Just, H., Holubarsch, C., Scholz, H. (eds) Inotropic Stimulation and Myocardial Energetics. Steinkopff, Heidelberg. https://doi.org/10.1007/978-3-662-07908-9_10
Download citation
DOI: https://doi.org/10.1007/978-3-662-07908-9_10
Publisher Name: Steinkopff, Heidelberg
Print ISBN: 978-3-662-07910-2
Online ISBN: 978-3-662-07908-9
eBook Packages: Springer Book Archive